Catheter-related thrombosis may lead to catheter infections and failure, further deep venous thrombosis, and pulmonary embolism. Recognizing the risk factors for catheter-related thrombosis is extremely important to inform the development of catheter care guidelines.
Methods:
Data were collected from a total of 1,532 patients who had undergone venous catheterization, including indwelling catheterization from 19 March 2019 to 30 March 2019 in the Sun Yat-sen Memorial Hospital. The factors for which data were to be collected included the patients’ physical characteristics, catheter-related factors, and catheter care-related factors. Logistic regression analysis, the chi-squared test, Fisher’s exact test, and the t-test were used to analyze the data.
Results:
Of the 1,532 patients studied, 28 developed intraductal thrombi, and of the factors analyzed, malignancy, a catheterization history, a history of thrombophilia, surgery during the week before catheterization, the catheterization duration, and anticoagulant therapy were significant risk factors associated with catheter-related thrombosis (all p < 0.05). There were no significant associations between the catheter brand, the number of lumens, the insertion direction, or the factors associated with catheter care and catheter-related thrombosis (all p > 0.05).
Conclusion:
Our study incorporated clear and systematic risk factors associated with catheter-related thrombosis. Malignancy, history of thrombophilia, history of catheterization, surgery during the week before catheterization, and catheterization duration were associated with increased risks of catheter-related thrombosis. Prophylactic anticoagulation was effective for preventing and treating catheter-related thrombosis.
WilimasJAHudsonMRaoB, et al. Late vascular occlusion of central lines in pediatric malignancies. Pediatrics1998; 101: E7.
5.
MassicotteMPDixDMonagleP, et al. Central venous catheter related thrombosis in children: analysis of the Canadian registry of venous thromboembolic complications. J Pediatr1998; 133: 770–776.
6.
SallahSWanJYNguyenNP.Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost2002; 87: 575–579.
7.
BlomJWDoggenCJOsantoS, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA2005; 293: 715–722.
8.
ChewHKWunTHarveyD, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med2006; 166: 458–464.
9.
KyriaziVTheodoulouE.Assessing the risk and prognosis of thrombotic complications in cancer patients. Arch Pathol Lab Med2013; 137: 1286–1295.
10.
StreiffMBHolmstromBAshraniA, et al. Cancer-associated venous thromboembolic disease, Version 1.2015. J Natl Compr Canc Netw2015; 13: 1079–1095.
11.
GorterKAStehouwerMCVan PutteBP, et al. Acidosis induced by carbon dioxide insufflation decreases heparin potency: a risk factor for thrombus formation. Perfusion2017; 32: 214–219.
12.
SaberWMouaTWilliamsEC, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost2011; 9: 312–319.
13.
DebourdeauPChahmiDKZammitC, et al. [Venous thromboembolism associated with long-term use of central venous catheters in cancer patients]. Pathol Biol (Paris)2008; 56: 211–219.
14.
DebourdeauPKassab ChahmiDLe GalG, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol2009; 20: 1459–1471.
15.
DebourdeauPFargeDBeckersM, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost2013; 11: 71–80.
16.
HookeC.Recombinant tissue plasminogen activator for central venous access device occlusion. J Pediatr Oncol Nurs2000; 17: 174–178.
17.
AndrisDAKrzywdaEASchulteW, et al. Pinch-off syndrome: a rare etiology for central venous catheter occlusion. J Parenter Enteral Nutr1994; 18: 531–533.
18.
VersoMAgnelliG.Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol2003; 21: 3665–3675.
19.
KuhleSKoloshukBMarzinottoV, et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res2003; 111: 227–233.
20.
RosovskyRPKuterDJ.Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management. Hematol Oncol Clin North Am2005; 19: 183–202, vii.
21.
BoersmaRSJieKSVerbonA, et al. Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol2008; 19: 433–442.
22.
MonrealMRaventosALermaR, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines: a prospective study. Thromb Haemost1994; 72: 548–550.
23.
FrankDAMeuseJHirschD, et al. The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis2000; 10: 271–275.
24.
KhoranaAAFrancisCWCulakovaE, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost2007; 5: 632–634.
25.
DonnellanEKevaneBBirdBR, et al. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol2014; 21: 134–143.
26.
RongYPostDEPieperRO, et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res2005; 65: 1406–1413.
27.
ReginaSValentinJBLachotS, et al. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem2009; 55: 1834–1842.
28.
NCCN clinical practice guidelines in cancer-associated venous thromboembolic disease (Version I) [DB/OL], 2019, http://www.nccn.org
29.
GerotziafasGTMaheIElalamyI.New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag2014; 10: 423–436.
30.
PrinsMHLensingAWBrightonTA, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol2014; 1: e37–e46.
31.
KhoranaAAVadhan-RajSKudererNM, et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial. Rationale and design of the CASSINI trial. Thromb Haemost2017; 117: 2135–2145.
32.
StreiffMBHolmstromBAngeliniD, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Canc Netw2018; 16: 1289–1303.
33.
LeeJHHyunDGChoiCM, et al. A retrospective study on efficacy and safety of rivaroxaban and dalteparin for long-term treatment of venous thromboembolism in patients with lung cancer. Respiration2019; 98: 203–211.
34.
JacksonLMO’GormanPJO’ConnellJ, et al. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM1997; 90: 183–188.
35.
NguyenGCBernsteinCNBittonA, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology2014; 146: 835–848.
36.
LismanT.Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease. Cell Tissue Res2018; 371: 567–576.
37.
PageCPitchfordS.Neutrophil and platelet complexes and their relevance to neutrophil recruitment and activation. Int Immunopharmacol2013; 17: 1176–1184.
38.
WolbergASAlemanMMLeidermanK, et al. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited. Anesth Analg2012; 114: 275–285.
39.
WatsonTShantsilaELipGY.Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet2009; 373: 155–166.
40.
ElmoamlySMattarMYacoubMF, et al. Can biomarkers of coagulation, platelet activation, and inflammation predict venous thromboembolism in patients with haematological malignancies?Acta Haematol2019; 141: 245–253.
41.
McGoldrickDMRedmondHP.Venous thromboembolism prophylaxis risk assessment in a general surgery cohort: a closed-loop audit. Ir J Med Sci2017; 186: 743–745.
42.
Baumann KreuzigerLJaffrayJCarrierM. Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults. Thromb Res2017; 157: 64–71.
43.
ParientiJJMongardonNMegarbaneB, et al. Intravascular complications of central venous catheterization by insertion site. N Engl J Med2015; 373: 1220–1229.
44.
MerrerJDe JongheBGolliotF, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA2001; 286: 700–707.
45.
ZhongLWangHLXuB, et al. Normal saline versus heparin for patency of central venous catheters in adult patients: a systematic review and meta-analysis. Crit Care2017; 21: 5.
46.
IngleRGAgarwalAS.Pre-filled syringe: a ready-to-use drug delivery system: a review. Expert Opin Drug Deliv2014; 11: 1391–1399.
